Back to News
Dec 8, 2025 4:00 PM

Eli Lilly's Leukemia Drug Matches Johnson & Johnson's Imbruvica In Untreated Patients

On Sunday, Eli Lilly and Co. (NYSE:LLY) shared results from the Phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who were treatment-naïve or were BTK inhibitor-naïve.

Eli Lilly stock is showing weakness. Why is LLY stock trading lower?

Johnson & Johnson’s (NYSE:LLY) Imbruvica is a covalent BTK inhibitor.

Pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib (87.0% versus 78.5%) in the intent-to-treat ...